Senior Vice President and Chief Human Resources Officer of HCA sells 4,010 shares in insider sale

Jennifer Berres, the Senior Vice President and Chief Human Resources Officer of HCA, recently divested 4,010 shares of the company on February 11, 2026, for an estimated value of $2,017,030. This transaction, which was reported in a recent filing with the Securities and Exchange Commission, represents approximately 20% of Berres’ holdings of this particular class of stock. As a result of this sale, Berres now retains ownership of 16,003 shares of HCA stock.

Over the past six months, insiders at HCA have engaged in twelve transactions involving the company’s shares. Notably, all of these transactions have been sales, with zero purchases recorded. Chief Executive Officer Samuel N Hazen led the pack with seven sales, amounting to 42,877 shares with a total estimated value of $21,483,274. Following suit, Jennifer Berres conducted two additional sales of 8,020 shares, valued at $4,126,950. Moreover, Michael S. Cuffe, the Executive Vice President and Chief Clinical Officer, and Michael R. Mcalevey, the Executive Vice President and Chief Legal & Administrative Officer, have each sold shares of HCA, amounting to 5,336 shares and 3,892 shares, respectively.

On the institutional front, hedge fund activity revolving around HCA has witnessed significant movement. A total of 583 institutional investors have increased their holdings of HCA stock, while 652 have decreased their positions in the latest quarter. Noteworthy transactions include UBS AM, a distinct business unit of UBS Asset Management Americas LLC, adding 1,465,455 shares to their portfolio in the third quarter of 2025, representing an estimated value of $624,576,921. Conversely, Longview Partners (Guernsey) Ltd opted to reduce its holdings by shedding 1,287,869 shares from its portfolio, amounting to $548,889,767. Similarly, other institutional investors such as Pacer Advisors, Price T Rowe Associates Inc, and Diamond Hill Capital Management Inc have made adjustments to their portfolio positions as well.

In terms of financial performance, HCA reported revenues of $19.5 billion in the fourth quarter of 2025, reflecting a 6.72% increase compared to the corresponding period in the prior year. This growth trajectory underscores the company’s robust operational performance and market positioning. Investors and analysts closely monitor the financial performance of HCA, with a particular focus on revenue generation and profitability metrics.

Additionally, Members of Congress have also taken an interest in trading HCA stock, with two transactions recorded in the past six months. Notably, Representative Lisa C. McClain made one purchase and one sale of HCA stock, indicating congressional interest in the company’s financial performance and market dynamics.

In conclusion, HCA’s recent insider trading activity, institutional investor movements, financial performance, and congressional interest underscore the company’s strategic positioning, financial health, and market outlook within the healthcare sector. Investors and analysts continue to closely monitor HCA’s stock performance and operational updates to gauge the company’s growth trajectory and long-term prospects in the market.